Luminex Corp, Austin, Tex, has received FDA clearance and CE marking for a new in vitro diagnostic system, the Aries M1 system. Designed for low-throughput clinical labs, the Aries M1 system is a fully integrated, sample-to-answer platform for performing real-time polymerase chain reaction assays.

The system is designed to empower satellite clinical laboratories to take advantage of the same benefits as Luminex’s high-throughput Aries system, with features such as an intuitive system interface, stat or batch testing, and true walkaway capability. The system extracts, amplifies, and detects nucleic acid targets from a variety of sample types. Once the cassettes are loaded onto the instrument, results are generated without additional technical intervention. The system can process up to six different samples, and one to six assays, at a time.

Homi Shamir, Luminex.

Homi Shamir, Luminex.

“In developing the Aries family of systems, we listened closely to the needs of our customers and crafted these products to increase laboratory efficiency, ensure result accuracy, and fit seamlessly into today’s lean laboratory,” says Homi Shamir, president and CEO of Luminex. “We are now adding another system based on customer feedback, and in doing so, expanding our market reach. Luminex now has the broadest offering of lowplex and highplex sample-to-answer systems for clinical laboratories performing molecular diagnostic testing. And, with the acquisition of Nanosphere behind us, we can focus on continuing to move products in our pipeline toward commercialization and realizing the value in our newly acquired asset.”

For more information, visit Luminex.